MAZE

Maze is a freshly public, clinical-stage genetics company whose value rests entirely on two early therapeutic candidates (MZE829 and MZE782) and its Compass target-discovery platform — none of which generate product revenue. The 1,916% jump in shares outstanding to 49.3M confirms a recent IPO, and the $168M of 'revenue' carried at FY2024 with $52.2M of net income almost certainly reflects a lumpy collaboration/license payment, not a recurring business: by FY2025 revenue is unavailable while the company swung to a -$131M net loss and a -$143M operating loss. The headline 8.5x P/S is therefore meaningless — it is priced off non-recurring collaboration income, not a sustainable top line.

The balance sheet looks superficially clean — $355M equity against just $42.2M of liabilities (0.12x), $350M current assets vs $22.6M current liabilities — but the number that matters is cash burn. Operating cash flow was -$112M and R&D rose 30% to $108M, against only $189M of cash and equivalents. That is roughly 1.7 years of runway with the burn rate still climbing, which all but guarantees a dilutive raise (or partnering on unfavorable terms) before the lead programs deliver pivotal data. Accumulated deficit already sits at -$490M.